NEW YORK, April 22, 2015 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt"), Lightlake's partner for treating opioid overdose with intranasal naloxone, successfully completed a clinical study of intranasal naloxone.
The pharmacokinetic study compared intranasal naloxone with an injectable formulation of naloxone. The study met its objectives and demonstrated the intranasal formulation of naloxone delivered the targeted naloxone dose as expected. Naloxone is a U.S. Food and Drug Administration (FDA) approved agent that reverses the effects of opioid overdose. Presently, all FDA approved formulations of naloxone are injectable products. Adapt is collaborating with the U.S. National Institute on Drug Abuse (NIDA) to develop a nasal naloxone formulation that would be suitable for use in the community setting by non-medically trained personnel.
"This important study builds on the first NIDA Lightlake collaborative pharmacokinetic study. It continues to demonstrate that nasal naloxone is a very promising treatment for the reversal of opioid overdose with great potential to be used in the community," stated Arvind Agrawal, Executive Vice President, Medical Affairs, at Lightlake. He added, "We have found that many caregivers in the community setting worry about accessing and administering injectable naloxone. Pharmacokinetic studies provide a regulatory path to bridging between formulations. Thus nasal naloxone could provide non-medically trained personnel with a simple and easily accessible tool to prevent death due to opioid overdose."
According to CDC WONDER, an information resource of the Centers for Disease Control and Prevention (CDC), opioid overdose led to the loss of over 26,000 lives in America in 2013, a four-fold increase since 1999. The majority of deaths arose in a community setting (mostly at home) and approximately 70% were caused by prescription opioids.
In December 2014, Lightlake announced a licensing deal with a subsidiary of Adapt Pharma Limited. In exchange for licensing its opioid overdose reversal treatment, Lightlake could receive potential development and sales milestone payments of more than $55 million, plus up to double-digit royalties.
About Lightlake Therapeutics Inc.
Lightlake Therapeutics Inc., a biopharmaceutical company, is using its expertise in opioid antagonists to build a platform of innovative intranasal naloxone solutions to common addictions and related disorders. Lightlake has entered into a licensing deal with a subsidiary of Adapt Pharma Limited with respect to a treatment to reverse opioid overdoses, which have reached epidemic proportions in the United States. Lightlake also has collaborated on clinical trials with the National Institute on Drug Abuse, part of the National Institutes of Health, with respect to this treatment. In addition, Lightlake has completed a Phase II clinical trial to treat Binge Eating Disorder. For more information please visit: http://www.lightlaketherapeutics.com.
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
Lightlake Therapeutics Inc.
445 Park Avenue, 9th Floor
New York, NY 10022
Dr. Roger Crystal, CEO
SOURCE Lightlake Therapeutics Inc.